China Resources Pharmaceutical Group Limited (CHINARES PHARMA) filed its monthly return for the period ended 31 July 2026, confirming that the total number of issued ordinary shares remained unchanged at 6.28 billion. No treasury shares were held or cancelled during the month.

The company verified compliance with the Hong Kong Main Board’s minimum public-float requirement of 25%, indicating sufficient free-float liquidity.

Under the approved share-option scheme (12 December 2017), CHINARES PHARMA reported no outstanding options at month-end. However, up to 628.45 million additional shares may still be issued under the existing mandate, offering future flexibility for equity-based incentives.

The filing noted no warrants, convertibles, or other share-issuance arrangements, and no movements in authorised or registered share capital.

The monthly return was submitted on 3 August 2026 by Company Secretary Wan Wing Yi Carol.